2 years ago
CRBP
AnalystsJeff JonesJeff Jones's Stock Forecasts
AnalystsJeff Jones
Analyst Ranking
Top 7%
#327 out of 5217 analysts
Average Return
+27.85%
Win Rate
38%42 out of 112
Risk vs Reward
Poor
Good
Jeff Jones's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Corbus Pharmaceuticals Holdings IncCRBP | +771.54% | $6.15 | $53.60 | 2023-08-09 - 2024-08-08 | Buy |
Fusion Pharmaceuticals IncFUSN | +728.85% | $2.60 | $21.55 | 2023-09-29 - 2024-06-03 | Buy |
Alumis IncALMS | +441.91% | $4.82 | $26.12 | 2025-02-10 - 2026-02-09 | Buy |
Zura Bio LtdZURA | +409.92% | $1.21 | $6.17 | 2025-05-09 - 2026-03-13 | Buy |
Corbus Pharmaceuticals Holdings IncCRBP | +369.82% | $9.31 | $43.74 | 2023-05-10 - 2024-05-09 | Buy |
Jeff Jones Analyst Color
Get additional color on Jeff Jones's coverage of popular stocks
Jeff Jones's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Pharming Group NvPHAR | 1 | Buy | $41.00 | +182.56% | Reiterates | 3 days ago |
Corvus Pharmaceuticals IncCRVS | 7 | Buy | $33.00 | +115.40% | Reiterates | 3 days ago |
Corbus Pharmaceuticals Holdings IncCRBP | 11 | Buy | $57.00 | +505.74% | Maintains | 6 days ago |
Arrivent Biopharma IncAVBP | 4 | Buy | $50.00 | +109.21% | Reiterates | 10 days ago |
Pelthos Therapeutics IncPTHS | 3 | Buy | $60.00 | +144.90% | Maintains | 2 months ago |
Kymera Therapeutics IncKYMR | 7 | Buy | $120.00 | +51.84% | Maintains | 3 months ago |
Ventyx Biosciences IncVTYX | 10 | Buy | $14.00 | 0.00% | Maintains | 5 months ago |
Chemomab Therapeutics LtdCMMB | 7 | Buy | $25.00 | +1,266.12% | Maintains | 7 months ago |
Y Mabs Therapeutics IncYMAB | 4 | Buy | $15.00 | +74.22% | Maintains | 10 months ago |
Alumis IncALMS | 3 | Buy | $25.00 | +0.77% | Maintains | 10 months ago |
Zura Bio LtdZURA | 4 | Buy | $17.00 | +175.53% | Maintains | 10 months ago |
Immunocore Holdings PLCIMCR | 2 | Buy | $86.00 | +178.68% | Maintains | 10 months ago |
Evolent Health IncEVH | 4 | Buy | $18.00 | N/A | Maintains | a year ago |
Perspective Therapeutics IncCATX | 6 | Buy | $16.00 | N/A | Maintains | a year ago |
Cellectar Biosciences IncCLRB | 4 | Buy | $360.00 | N/A | Maintains | a year ago |
Pliant Therapeutics IncPLRX | 6 | Buy | $45.00 | N/A | Maintains | 2 years ago |
Seres Therapeutics IncMCRB | 3 | Buy | $80.00 | N/A | Maintains | 2 years ago |
Patterson Companies IncPDCO | 3 | Hold | $30.00 | N/A | Maintains | 2 years ago |
Fusion Pharmaceuticals IncFUSN | 3 | Buy | $15.00 | N/A | Maintains | 2 years ago |
Bio Green Med Solution IncBGMS | 3 | Buy | $28,800.00 | N/A | Maintains | 3 years ago |
Point Biopharma Global IncPNT | 2 | Buy | $13.00 | N/A | Reiterates | 3 years ago |
Novan IncNOVNQ | 2 | Buy | $8.00 | N/A | Maintains | 3 years ago |
Pmv Pharmaceuticals IncPMVP | 5 | Buy | $15.00 | N/A | Reiterates | 3 years ago |
An2 Therapeutics IncANTX | 1 | Buy | $24.00 | N/A | Maintains | 3 years ago |
Moleculin Biotech IncMBRX | 2 | Buy | $1,875.00 | N/A | Reiterates | 3 years ago |
Prometheus Biosciences IncRXDX | 6 | Buy | $150.00 | N/A | Maintains | 3 years ago |
Evaxion AEVAX | 2 | Buy | $1,100.00 | N/A | Maintains | 3 years ago |
Notable Labs LtdNTBLQ | 1 | Buy | $5.50 | N/A | Assumes | 4 years ago |
Rain Oncology IncRAIN2 | 1 | Buy | $15.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.